Comparison of M22-based ELISA and Human-TSH-Receptor-based Luminescence Assay for the Measurement of Thyrotropin Receptor Antibodies in Patients with Thyroid Diseases

Abstract

Previously, a new procedure for measuring serum TSH receptor autoantibodies (TRAb) was reported in which the autoantibodies inhibit binding of a human monoclonal thyroid stimulating antibody M22 to TSHR-coated ELISA plate wells (TRAb ELISA). The aim of the present study was to evaluate the clinical performance of this assay in comparison to the second generation TRAb assay (TRAb LIA) based on the recombinant human TSH-receptor and chemiluminescence technology (TRAb LIA). Among the 158 patients, 84 patients suffered from Graves’ disease (GD), 34 patients had Hashimoto's thyroiditis (HT), and 40 patients had euthyroid nodular thyroid disease (NTD) without signs of autoimmunity. TRAb measurements were performed according to the manufacturer's instructions. Out of 84 GD patients, 80 (95.2%) were TRAb positive as detected by the TRAb LIA. One GD patient had TRAb values within the grey zone (1.0–1.5 IU/l). All patients with HT and NTD were negative except in 6 (8.1%) cases whose TRAb values were within the grey zone. On the basis of the recommended cutoff value (TRAb 1.0 IU/l), the TRAb ELISA found 78 of 84 (92.9%) GD patients to be TRAb positive. None of the patients with HT, but two cases (5.0%) with NTD were TRAb positive. The diagnostic sensitivity of the TRAb LIA and TRAb ELISA assays was 95.2 and 92.9%, while the specificity was 100% and 97.3%, respectively. There was a close correlation (r=0.968, p<0.0001) between both assays in 84 patients with GD. Additionally, the between-run imprecision close to the cutoff limit was assessed. The calculated between-run coefficient of variation (CV) of the TRAb ELISA was 28.2% at the recommended cutoff value of 1.0 IU/l. Due to the evaluated imprecision data we propose a higher cutoff value correlating with a between-run CV of 20% (functional assay sensitivity). Our results indicate that due to a worse imprecision the TRAb ELISA has a slightly lower sensitivity and specificity compared to the TRAb LIA assay. These findings suggest that the M22 monoclonal antibody-based TRAb ELISA is not as reliable as other second generation TRAb assays in the diagnosis of Graves’ diseases.

Key words

thyrotropin receptor antibody - second generation TRAb assays - Graves’ disease - M22 monoclonal antibody

References

• 1 Weetman AP. Cellular immune responses in autoimmune thyroid disease.  Clin Endocrinol. 2004;  61 405-413
• 2 Guarneri F, Benvenga S. Environmental factors and genetic background that interact to cause autoimmune thyroid disease.  Cur Opin Endocrinol Diab Obes. 2007;  14 398-409
• 3 Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases.  Endocr Rev. 2007;  28 492-520
• 4 Rapoport B, MacLachlan SM. The thyrotropin receptor in Graves’ disease.  Thyroid. 2007;  17 911-922
• 5 Rees Smith B, Sanders J, Furmaniak J. TSH receptor antibodies.  Thyroid. 2007;  17 928-938
• 6 Schott M, Scherbaum WA, Morgenthaler NG. Thyrotropin receptor autoantibodies in Graves’ disease.  Trends Endocrinol Metab. 2005;  16 243-248
• 7 Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves’ disease and multinodular toxic goitre: a comparison of two competitive binding assays.  Clin Endocrinol (Oxf). 2001;  55 381-390
• 8 Paunkovic N, Paunkovic J. Does autoantibody-negative Graves’ disease exist? A second evaluation of the clinical diagnosis.  Horm Metab Res. 2006;  38 53-56
• 9 Abalovich M, Amino N, Barbour LA, Cobin RH, Groot LJ, Glinoer D, Mandel SJ, Stagnaro-Green AL. Management of thyroid dysfunction during pregnancy and postpartum: an endocrine society clinical practice guideline.  J Clin Endocrinol Metab. 2007;  92 1-47
• 10 Luton D, Le Gac I, Vuillard E, Castanet M, Guibourdenche J, Noel M, Toubert ME, Léger J, Boissinot C, Schlageter MH, Garel C, Tébeka B, Oury JF, Czernichow P, Polak M. Management of Graves’ disease during pregnancy: the key role of fetal thyroid gland monitoring.  J Clin Endocrinol Metab. 2005;  90 6093-6098
• 11 Chan GW, Mandel SJ. Therapy insight: management of Graves' dis-ease during pregnancy.  Nat Clin Pract Endocrinol Metab. 2007;  3 470-478
• 12 Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves’ disease.  Thyroid. 2005;  15 1047-1054
• 13 Izumi Y, Takeoka K, Amino N. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiated relapse of Graves’ thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves’ disease.  Endocr J. 2005;  52 493-497
• 14 Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves’ hyperthyroidism.  Eur J Endocrinol. 2005;  153 489-498
• 15 Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, Reschke K, Hackenberg K, Dettmann J, Prehn B, Hirche H, Mann K. Relapse of Graves’ disease after successful outcome of antithyroid drug therapy: Results of a prospective randomized study on the use of levothyroxine.  Thyroid. 2002;  12 1119-1128
• 16 Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, Martino ED, Rosei EA. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves’ disease: a 120 months prospective study.  Endocr J. 2007;  54 713-720
• 17 Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Nersita R, Iorio S, Amato G, Braverman LE, Roti E. Serum thyrotropin receptor antibodies concentrations in patients with Graves’ disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.  Thyroid. 2006;  16 295-302
• 18 Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, Seiissler J. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves’ disease.  Horm Metab Res. 2004;  36 92-96
• 19 Schott M, Eckstein A, Willenberg HS, Nguyen T-B-T, Morgenthaler NG, Scherbaum WA. Improved prediction of relapse of Graves’ thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies.  Horm Metab Res. 2007;  39 56-61
• 20 Schott M, Feldkamp J, Bathan C, Fritzen R, Scherbaum WA, Seissler J. Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation.  Horm Metab Res. 2000;  32 429-435
• 21 Morgenthaler NG. New assay systems for thyroid receptor antibodies.  Current Opin Endocrinol Diabetes. 1999;  6 251-260
• 22 Costagliola S, Morgenthaler NG, Hoermann R, Badenhoop K, Struck J, Freitag D, Poertl S, Weglohner W, Hollidt JM, Quadbeck B, Dumont JE, Schumm-Draeger P-M, Bergmann A, Mann K, Vassart G, Usadel K-H. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves’ disease.  J Clin Endocrinol Metab. 1999;  84 90-97
• 23 Sanders J, Jeffreys J, Depraetere H, Richards T, Evans M, Kiddie A, Brereton K, Groenen M, Oda Y, Furmaniak J, Rees Smith B. Thyroid-stimulating monoclonal antibodies.  Thyroid. 2002;  12 1043-1050
• 24 Rees Smith B, Bolton J, Young S, Collyer A, Weeden A, Bradburg J, Weightman D, Perros P, Sanders J, Furmaniak J. A new assay for thyrotropin receptor autoantibodies.  Thyroid. 2004;  14 830-835
• 25 Kamijo K. TSH-receptor antibody measurement in patients with various thyrotoxicosis and Hashimoto's thyroiditis: a comparison of two two-step assays, coated plate ELISA using porcine TSH-receptor and coated tube radioassay using human recombinant TSH-receptor.  Endocr J. 2003;  50 113-116
• 26 Kamijo K. TSH-receptor antibodies determined by the first, second and third generation assays and thyroid-stimulating antibody in pregnant patients with Graves' disease.  Endocr J. 2007;  54 619-624

1 Both authors contributed equally to this work.

Correspondence